Why the study?
Does nadolol reduce breakthrough arrhythmic events compared to selective β-blockers in patients with CPVT?
Does nadolol reduce breakthrough arrhythmic events compared to selective β-blockers in patients with CPVT?
In patients with CPVT, nadolol is associated with fewer arrhythmic events than selective β-blockers, and ICDs effectively prevent sudden cardiac death.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Werf et al. (2024) conducted a review in Catecholaminergic polymorphic ventricular tachycardia (CPVT) (n=216). Nadolol vs. Selective β-blockers was evaluated on Breakthrough arrhythmic events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: